Please provide your email address to receive an email when new articles are posted on . Omeros Corp. announced that the U.S. Food and Drug Administration has approved the use of phenylephrine and ...

The specialist ophthalmology clinic will offer the program to patients, enabling them to access its established surgical pathway within its ...

Omeros reported positive data from its Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302 met its primary endpoint by demonstrating ...

American Hospital Supply Corp., a unit of Baxter Travenol Laboratories Inc., has received approval from the Food and Drug Administration to market two kinds of intraocular lenses that correct vision ...

-- Submission of New Drug Application Planned for First Half of 2013-- -- Company to Host Conference Call Today at 9:00 a.m. EST-- SEATTLE, Nov. 5, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: ...

Raleigh, NC - February 04, 2026 - PRESSADVANTAGE - Porter Ophthalmology announced the release of a comprehensive new ...

SEATTLE, June 2, 2014--Omeros Corporation OMER +8.64% today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use ...

SEATTLE, Jan. 22, 2013 /PRNewswire/ – Omeros Corporation (OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical ...

Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.

(Reuters Health) - Seniors who get new lenses implanted during cataract surgery may not only see better but also experience better sleep, suggests a new study of how light entering the eye regulates ...

Omeros reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. This multicenter, double-blind, ...